LUCD trades 85.2% below Wall Street's consensus target of $2.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LUCD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Lucid Diagnostics Inc. (LUCD) has a Wall Street consensus price target of $2.00, based on estimates from 6 covering analysts. With the stock currently trading at $1.08, this represents a potential upside of +85.2%. The company has a market capitalization of $110M.
Analyst price targets range from a low of $2.00 to a high of $2.00, representing a 0% spread in expectations. The median target of $2.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LUCD trades at a trailing P/E of -1.6x. Analysts expect EPS to grow +46.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
GKOSGlaukos Corporation | $7.6B | $130.68 | $151.25 | +15.7% | Buy | — | 24 |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
NNOXNano-X Imaging Ltd. | $109M | $1.67 | $18.00 | +977.8% | Buy | — | 5 |
CDXSCodexis, Inc. | $234M | $2.57 | $5.00 | +94.6% | Buy | — | 14 |
EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
NTRANatera, Inc. | $33.1B | $231.41 | $259.88 | +12.3% | Buy | — | 27 |
GUTSFractyl Health, Inc. Common Stock | $62M | $0.86 | $5.00 | +482.5% | Buy | — | 3 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
EWEdwards Lifesciences Corporation | $50.4B | $87.36 | $96.55 | +10.5% | Buy | 29.0x | 48 |
Quick answers to the most common questions about buying LUCD stock.
The consensus Wall Street price target for LUCD is $2, representing 85.2% upside from the current price of $1.08. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LUCD has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $2 implies 85.2% upside from current levels.
LUCD's current price is $1.08 with a consensus target of $2 (85.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $2 for LUCD, while the most conservative target is $2. The consensus of $2 represents the median expectation. These targets typically reflect 12-month expectations.
LUCD is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LUCD stock forecast based on 6 Wall Street analysts shows a consensus price target of $2, with estimates ranging from $2 (bear case) to $2 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on LUCD, with a "Buy" consensus rating and $2 price target (85.2% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LUCD analyst price targets range from $2 to $2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $2 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.